Background: Of the three transforming growth factor (TGF)-␤ isoforms known, TGF␤1 deficits have been widely reported in Alzheimer's disease (AD) and studied as a potential therapeutic target. In contrast, the status of TGF␤2, which has been shown to mediate amyloid-␤ (A␤)-mediated neuronal death, are unclear both in AD and in Lewy body dementias (LBD) with differential neuritic plaque and neurofibrillary tangle burden. Objective: To measure neocortical TGF␤2 levels and their correlations with neuropathological and clinical markers of disease severity in a well-characterized cohort of AD as well as two clinical subtypes of LBD, dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD), known to manifest relatively high and low A␤ plaque burden, respectively. Methods: Postmortem samples from temporal cortex (BA21) were measured for TGF␤2 using a Luminex-based platform, and correlated with scores for neuritic plaques, neurofibrillary tangles, ␣-synuclein pathology, dementia severity (as measured by annual decline of Mini-Mental State Examination scores) as well as soluble and total fractions of brain A␤ 42 . Results: TGF␤2 was significantly increased in AD and DLB, but not in PDD. TGF␤2 also correlated with scores for neurofibrillary tangles, Lewy bodies (within the LBD group), dementia severity, and soluble A␤ 42 concentration, but not with neuritic plaque scores, total A␤ 42 , or monomeric ␣-synuclein immunoreactivity. Conclusions: TGF␤2 is increased in the temporal cortex of AD and DLB, and its correlations with neuropathological and clinical markers of disease severity as well as with soluble A␤ 42 load suggest a potential pathogenic role in mediating the neurotoxicity of non-fibrillar A␤. Our study also indicates the potential utility of targeting TGF␤2 in pharmacotherapeutic approaches to AD and DLB.

